News has been ok!Nothing earth shattering but steady as she goes.Singapore progress very good and should come to fruition in the near term
Printable View
Read it the old fashioned way here.
Still making losses.
As anyone should have expected. The recent announcements did not indicate that instant profitability would result.
There is still a great deal of investment required to leverage and maximise the opportunities. While profitability is probably much closer and much more certain - it is still a prospect not a reality.
Price per test between $NZD1100 and $NZD3400. Marginal cost of test. $NZD100. Nice margin! Current tests 16,000 per annum. Existing lab capacity = 295,000 tests. KP and LCD will open a lot of doors. Future looks good to me.
If you wanted to make a quick buck (not looking at Sharesies investors) then the picture painted is not good.
On the other hand, the long term forecast looks good and the management is highly focused and not trying to take on more than they can handle. A singular focus on the USA makes sense. The medical profession is slow to change. That means a long lead time for sales but once you hook a customer they are unlikely to switch.
They are very focusing on most promising profitable regions such as US and Southeast Asia instead of EU, Canada, etc.
Please go easy on me as its my first post - Any ideas on the likely effect of inclusion on the NZX in Dec (if that happens?)
And a longterm hold in mine too.
Interesting to hear the two sides to covid-19.
Whilst it has, unsurprisingly, increased the uptake of home based testing it's also made it harder for sales staff to go out and sell (hadn't thought of that one).
But with the 2 recent big name customers signing on that minor negative shouldn't be too much of an issue.